Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock

DEVON, Pa., Jan. 18, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  All of the shares to be sold in the offering will be offered by Zynerba.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Zynerba intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.

Jefferies LLC and Piper Jaffray Co. are acting as

... read more at: http://finance.yahoo.com/news/zynerba-pharmaceuticals-announces-proposed-public-210513527.html

by